Childhood bacterial meningitis: antimicrobial use pattern and treatment outcomes: a prospective observational study

Background: Bacterial meningitis continues to be an important source of mortality and morbidity in infants and children throughout the world despite advances in antibiotics. Resource limited countries contribute more to the mortality and morbidity. We conducted this study to assess antimicrobial use pattern and determine treatment outcomes among children hospitalized with bacterial meningitis.

Study design: Prospective observational study was conducted among infants and children admitted to pediatric ward of Jimma University Specialized Hospital. The data was collected with pretested questionnaire and entered into Epi Data (version 3.1), then exported to SPSS (version 20.0) for analysis. Logistic regression analysis was made to determine independent predictors of poor outcomes.

Results: A total of 89 samples of patients which were treated for bacterial meningitis were analyzed. Ampicillin plus Gentamycin was used as initially antibiotic regimen in most young infants (86.8%); while majority of older infants and children (66.7%) initially managed with crystalline penicillin plus Chloramphenicol. Among patients those were treated, 67.4% improved without acute complication, while the remaining 32.6% had poor outcomes (9% died, 18% had delayed fever and 5.6% had acute neurologic complications). Change of antibiotics from empiric therapy was found to be independent predictor of poor outcomes in young infants (AOR= 4.42, 95% CI (1.01-19.44)). However, in older infants and children: irritability (AOR=38.39, 95% CI (1.78-829.36)) and seizure prior to admission (AOR=27.53, 95% CI (1.45-522.35)), initial antibiotic regimen with ceftriaxone plus gentamycin (AOR=66.48, 95% CI (3.16-1400.13)), and missed doses of antibiotics (AOR=47.33, 95% CI (2.14-1046.19)) were found to independently predict poor outcomes.

Conclusion: The antimicrobials use pattern in this study was nearly similar with the recommendation of national guideline. At discharge nearly one-fourth of the patients treated for bacterial meningitis experienced poor outcomes implying need revising management protocol of childhood bacterial meningitis.

Keywords: childhood, bacterial meningitis, antimicrobials, poor outcomes, Ethiopia
In general, the occurrence of adverse consequences of BM in developed countries is strongly reduced by vaccination strategies, advances in antibiotic treatment, and good care facilities. In contrast, those resource limited countries are exposed to a number of factors that lead them to be vulnerable to those consequences of BM. To mention some: (a) Non-implementation of vaccination programs against major meningeal pathogens; (b) Late presentation of patients, having been given antibiotics without a definite diagnosis in primary or private settings, consequently, many CSF samples do not show the causative agent; (c) Late and insufficient CSF culture and Gram-staining results even though they are basic for definitive diagnosis and guiding treatment; (d) Many hospitals cannot afford expensive third generation cephalosporin and rely on chloramphenicol and penicillin as the first-line antibiotic treatment for meningitis; and (e) Intensive care units are few and not always well staffed [11-15].

In African, children experience both the highest incidence rates [12] as well as the consequences of BM in the world [13]. In Ethiopia, BM alone accounts for about 6-8% of all causes of the hospital admissions and the case fatality rates associated with it is as high as 22-28%. It has remained a serious health concern in Ethiopia too for the past few decades. The consequences of all these lead to a considerable emotional, financial and human resource burden on the family as well as the health care system [15-18].

The causes of BM vary with ages in pediatrics. The most common bacterial causes of neonatal meningitis are Listeria monocytogenes (LM), Group B streptococcus (GBS) and *Escherichia coli* (*E. coli*) [19-22]; that are mainly acquired from the maternal birth canal during delivery. Whereas, the commonest etiologic agents in children beyond the neonatal period are: Haemophilus Influenzae Type b (HiB), *Neisseria meningitidis* and *Streptococcus pneumoniae* [16]. However, these are not the only organisms limited to pediatrics; alterations of host defense due to anatomic defects or immune deficits also increase the risk of meningitis from less common pathogens such as *Pseudomonas aeruginosa* and *Staphylococcus aureus* [23-26].

Appropriate empiric antimicrobial treatment should be initiated as soon as possible after the diagnosis is considered to reduce the risk of mortality and complications due to delay in treatment [27]. The choice of empiric antibiotics should take into consideration blood brain barrier (BBB) penetration, the local epidemiology, early versus late disease, resistance patterns and availability within resource constraints [28].

In resource limited settings the treatment of pediatric BM generally has two protocols based on age (under 2 months and above 2 months of age) [29]. Accordingly, for neonates and young infants (under 2 months of age) the first-line antibiotics are Ampicillin and Gentamicin and alternatives, a third-generation cephalosporin, such as Ceftriaxone [20] or Cefotaxime plus Gentamycin [30]. For infants and children (above 2 months of age) the first line is the combination of Penicillin G and Chloramphenicol and the alternative is Ceftriaxone [31-33], or Cefotaxime [16]. For patients not responding to the first line regimens, vancomycin plus ceftazidime can be considered.

Although the major burden of childhood BM occurring in the developing world, the most currently existing literature originated from wealthy countries [34]. As far as we know, limited studies have been done in our country regarding prevalence, etiology, diagnosis, antimicrobial sensitivity, and outcomes of meningitis [24-30]; however studies concerning treatment and its outcomes are still lacking. Therefore, the need for further study in our set up was unquestionable to assess antimicrobial use pattern and determine predictors of poor outcomes of childhood BM.

**Methods**

**Study design, period and setting**

From February 25 to April 29 2015, a prospective observational study was conducted at the pediatric ward of Jimma University Specialized Hospital (JUSH). JUSH is found in Jimma Town which is located 335 Km Southwest of Addis Ababa, the capital of Ethiopia. Currently JUSH is the only teaching and referral hospital in the southwestern part of the country. It has 450 beds and more than 750 staff of both professional and supportive. It provides services in different specialty areas for more than 15 million people of the catchment population [35].
Case identification  
**Inclusion criteria**

All pediatrics cases (01 day to 14 years of age) that were clinically suspected or confirmed as meningitis and started treatment for BM during the study period were included in the study. Meningitis was suspected if the patient was presented with any of the following signs of serious bacterial infection: lethargic, vomiting (≥ 3 episodes), decreased feeding or inability to breast feed, bulging fontanel (≤ 2 years), irritable, high-pitched cry, fever (auxiliary measurement ≥ 38°C), and headache (above 2 year), meningeal irritation signs (Kernig or Brudzinski signs or neck stiffness, ≥ 1 year). The presence of seizure, impaired consciousness (Blantyre Coma Scale <4 if < 9 months of age and <5 if ≥ 9 months of age), signs of raised intracranial pressure, unequal pupils, focal paralysis in any of the limbs, and irregular breathing on examination were considered critical for suspicion of meningitis [36]. However, lumbar puncture was performed to confirm the diagnosis after initiating antibiotic treatment once the infant has been stabilized.

**Exclusion criteria**

- Patients lost to follow within 7 days after starting treatment, and
- Children, in whom the initial diagnosis changed to others than BM like fungal, viral after they were included in the study.

Ethical considerations

Official ethical clearance was obtained from the institutional review board of JU, college of health sciences, and permission from the medical director of the hospital prior to data collection. A written patient consent was obtained from care givers or family in 2 local languages (Afan Oromo and Amharic) prior data collection. From the very beginning, they were assured that no personal identity would be disclosed, their participation was completely voluntary and that they could be free to withdraw at any time, and this could not affect the medical care that would be given to their child. Above all, the study procedures did not cause any harm to the patient.

Study definitions

Young infants: were defined in this study as those infants under 2 months of age; and older infants and children: were those infants and children whose age ranged from 2 months to 14 years based on the treatment protocol [5,8]. Therefore, Pediatrics according to the current study, included infants and children aged from 1 day to 14 years.

Bacterial meningitis were defined according to physician's clinical diagnosis, including either laboratory-confirmed or probable cases and if no changes in treatment considered until discharge or death to other causes of meningitis like fungal, tuberculosis.

Short term treatment outcomes: according to this study was defined as outcomes of BM detected only until discharge. These included: good and poor outcomes.

- Good outcome- which means improvement without acute complications
  - A sign of improvement: normalization of fever was considered as an indicator of improvement from BM since fever is the single most common presenting complaint in patients with BM [37]. In this study delayed fever was defined as fever persisted for more than 7 days [38]. For afebrile patients, other clinical features they presented with were followed for improvement.
  - Poor outcome– death within the ward, delayed fever, and developed acute neurologic complications during treatment or at discharge.
- Acute complication: was defined as any complication of BM detected until discharge.

Data collection and quality assurance

First, the data collectors (two hospital pharmacists) and a supervisor (pharmacist) were trained for two days before data collection. Since the focal point of the study was to insure the actual picture of the setup, all the data collectors, the executive program and the principal investigator restricted from interfering the management in the ward. They stuck with each patient twice a day (sunrise and afternoon) recording pertinent data based on the variables on the questionnaires. The supervisor and principal investigator thoroughly followed and coordinated the overall activities.

Pretest was performed and the instruments were modified accordingly, but the pretested samples were not included in the analysis. Frequencies were used to suss out for entry
errors, missed values and outliers. Any error identified is rectified immediately by revising the original data using the unique code.

**Statistical analysis**

The gathered data were entered into Epi data (version 3.1) and exported to statistical package for social science (SPSS) Version 20 for analysis. Discrete variables are expressed as counts (percentage) and continuous variables as means ± standard deviation (SD) or median and interquartile range (IQR). All continuous data were categorized based on standard cut off points, or mean / median to fit for logistic regression.

Univariate analysis was done for all independent variables to select possible candidates for multivariate logistic regression and the criterion for selection was p<0.25 from the univariate analysis. Lastly, an odds ratio (OR) and 95% confidence interval were employed to determine the precision of the study and the level of statistical significance was considered at p-value <0.05.

For the sake of analysis the main treatment outcomes of BM were categorized as good and poor outcomes. Risk factors of poor results for young infants and that of older infants and children might be different since they were disclosed to different treatment regimens. Hence, a separate analysis was done in the two groups and introduced as follows.

I) Risk factors for poor outcomes of BM in young infants

In order to determine their association with the incidence of poor outcomes, 5 potentially relevant predictors were chosen for multivariate analysis based on their significance from the univariate analysis with p<0.25 (TABLE 5). These were: (1) male gender, (2) mode of delivery, (3) severe dyspnea, (4) any antibiotic changes and (5) number of AB doses missed. In that location were no missing data on the 5 variables selected. Among the five possible risk factors, multivariate logistic regression identified only one, any antibiotic change to be an independent predictor of the poor outcomes.

II) Risk factors for poor outcomes of BM in older infants and children

The following seven nominees were chosen based on their p-value from univariate analysis results (TABLE 6). Factors with p<0.10 were selected, because the sample size for this age group was small (n=36) to allow higher p-value (<0.25) that would include more candidates. In that location were no missing data for all the seven selected variables. These were: (1) male gender, (2) irritability and (3) seizure prior to admission, (4) presence of any comorbidity, (5) initial AB regimen with Ceftriaxone plus Gentamycin or Ceftriaxone alone instead of Crystalline penicillin plus Chloramphenicol, (6) longer than 1 hour delay to treatment initiation from diagnosis and (7) missing one or more doses of AB during the handling course. From the seven potential risk factors, multivariate logistic regressions determined the following four independent predictors of poor outcomes of BM: (1) irritability and (2) seizure prior admission, (3) initial AB regimen with Ceftriaxone plus Gentamycin instead of Crystalline penicillin plus Chloramphenicol, and (4) missing 1 or 2 doses of AB during the treatment course compared to patients never missed.

Furthermore, multi-collinearity diagnostic test was done for all predictors of poor outcomes of childhood BM to see their impact in the regression model and the variance inflation factors (VIF) was utilized to assess the impact of collinearity among the variables. Hosmer-Lemeshow test was employed to examine the goodness-of-fit of the logistic regression model.

**Results**

Demographic and baseline characteristics of the patient

A total of 693 patients (285 young infants and 408 older infants and children) were admitted to the pediatric ward of JUSH during the study period. Among these, 102 patients diagnosed as meningitis and started treatment for BM. Thirteen patients were excluded from follow up due to the following reasons: 4 lost to follow up before 7 days of treatment, in 2 patients physician decided to stop therapy and in 7 patients diagnosis changed. Therefore, the analysis was done for a total of 89 patients that completed the whole course of treatment for BM and die within the ward after initiation of treatments for meningitis (FIGURE 1).

The basic demographic and baseline characteristics are summarized in TABLE 1. The median age of young infants was 6 days; whereas
older infants and children it was 27 month. The proportion of males were higher in both age groups; 66% (young infants) and 61.1% (older infants and children).

The median durations of illness before hospital presentation were 24 hours with IQR (7.0-72.0) for young infants, whereas, 72 hours with IQR (24.0-96.0) for older infants and children (TABLE 1). The two most common clinical characteristics at presentation for young infants were: inability to breast feed (84.9%) and fever (69.8%), followed by vomiting (49.1%) (FIGURE 2).

Nevertheless, the most usual features for older babies and children were fever (94.4%) and vomiting (80.6%), followed by headache, decreased feeding and seizure (each 61.1%) (FIGURE 3).

Lumbar puncture was done in 60 patients (67.4%) and conked out in the remaining 29 (32.6%) of cases. Among these, the causative

---

**Table 1. Age distribution of measles from 2010 to 2016.**

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>≤ 2months (n=53), N (%)</th>
<th>&gt;2months (n=36), N (%)</th>
<th>Total (n=89) N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median months (IQR)</td>
<td>0.2(0.03-0.93)</td>
<td>27 (9.8-72.0)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>35 (66)</td>
<td>22(61.1)</td>
<td>57 (64.0)</td>
</tr>
<tr>
<td>Female</td>
<td>18 (34)</td>
<td>14(38.9)</td>
<td>32 (36.0)</td>
</tr>
<tr>
<td>Birth weight (kg), mean (± SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 2.5</td>
<td>25 (75.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5-2.5</td>
<td>6 (18.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 1.5</td>
<td>2 (6.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestational age (in weeks)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;37</td>
<td>37 (69.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 37</td>
<td>12 (22.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mode of delivery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal</td>
<td>44 (83)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caesarian Section</td>
<td>9 (17)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunization history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fully immunized</td>
<td>19 (52.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not fully immunized</td>
<td>17 (47.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous history of hospital admission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0</td>
<td>3 (8.3)</td>
<td>3 (3.3)</td>
</tr>
<tr>
<td>No</td>
<td>53 (100)</td>
<td>33 (91.7)</td>
<td>86 (96.7)</td>
</tr>
<tr>
<td>Maternal history of fever or UTI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>12 (22.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>41 (77.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median duration of symptoms (hrs.), (IQR)</td>
<td>24 (7.0-72.0)</td>
<td>72 (24-96)</td>
<td></td>
</tr>
<tr>
<td>Mean body temperature (°C) at admission (± SD)</td>
<td>37.6 (36.7-38.5)</td>
<td>38.3 (37.4-39.2)</td>
<td></td>
</tr>
<tr>
<td>Lumbar puncture was done</td>
<td>29 (54.7)</td>
<td>31 (86.1)</td>
<td>60 (67.4)</td>
</tr>
<tr>
<td>Pneumococci</td>
<td>1 (1.9)</td>
<td>2 (5.6)</td>
<td>3 (3.4)</td>
</tr>
<tr>
<td>Meningococci</td>
<td>1 (2.8)</td>
<td>1 (1.1)</td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td>3 (8.3)</td>
<td>3 (3.4)</td>
<td></td>
</tr>
<tr>
<td>No microorganisms seen</td>
<td>20 (37.7)</td>
<td>16 (44.4)</td>
<td>36 (40.4)</td>
</tr>
</tbody>
</table>
### Lumbar puncture failed
- No reagent: 24(45.3) 5(13.9) 29(32.6)
- CSF WBC count was done: 26(49.0) 27(75.0) 53(59.6)
- CSF WBC count/mm³, median(IQR): 2(0.0-11.2) 2(0.0-12.0) 2(0.0-11.0)
- CSF protein analysis was done: 10/53 10/36 20(22.5)
- CSF protein (mg/dl), median (IQR): 64.0(32.0-128.0) 96.0(28.0-158.0) 80.0(32.0-150.0)
- CSF glucose analysis was done: 4/53 5/36 9/89(10.1)
- CSF glucose (mg/dl), median(IQR): 64.0(32.0-128.0) 96.0(28.0-158.0) 80.0(32.0-150.0)

### Presence of comorbidities
- Yes: 37(69.8) 21(58.3) 58(65.2)
- No: 16(30.2) 15(41.7) 31(34.8)

### Types of comorbidities
- Sepsis: 34(91.9) 6(28.6) 40(44.9)
- Malaria: 5(23.8) 5(5.6)
- Others (pertussis, HIV, impetigo, moderate diarrhea, SAM and anemia): 3(8.1) 10(47.6) 13(14.6)

SD- standard deviation, IQR- interquartile range, UTI- urinary tract infection, HIV-human immunodeficiency virus, SAM-sever acute malnutrition, CSF- cerebrospinal fluid

#### FIGURE 2. Clinical presentations prior to admission of younger infants treated for BM in JUSH during February 25- April 29, 2015.


Pathogens were identified by CSF stain only in 7 patients (7.9%): 3 pneumococcal, 3 H1B and 1 meningococcal. In 36 patients (40.4%), the result was reported as ’no microorganism was
seen', and in the remaining 17 patients (19.1%) there were no reagents to carry out the stain (TABLE 1).

From all pediatric patients admitted in this ward during the study period, 14.4% were diagnosed with bacterial meningitis (FIGURE 1). Most of the young infants (69.8%) had comorbidities, mainly of sepsis (34/37); whereas in older infants and children comorbidities of different types observed in 58% of the cases (TABLE 1).

Drug related factors
Factors related to drugs used for the management of childhood BM in the study population are summarized in TABLE 2. Most of the young infants (86.8%) were initially treated with empiric Ampicillin plus Gentamycin regimen. On the other hand, in the majority of the older infants and children (66.7%), the initial AB regimen was crystalline penicillin plus Chloramphenicol. The median duration of treatment from diagnosis for both age groups was similar, 1 hour with IQR (0.3-3.0) for young infants and (0.5-2.0) for older infants and children. By considering the delayed presentation and delay in hospital for treatment, these two durations were added to give another important factor, delay of treatment for initial illness. Therefore, the median delay for treatment from initial illness was 32 hours (10.2-73.5) for young infants, whereas 73 hours (25.4-98.4) for older infants and children.

Treatment outcomes of childhood BM
The median duration of improvement after treatment were 6 days (3.0-9.2) for young infants, whereas 4 days (3.0-7.0) for older infants and children. Nearly 72% of the young infants and 61% of older infants and children improved within 7 days of treatment. Altogether, 67.4% of the patients improved without acute complication; while, 9% died, 18% had delayed fever and 5.6% had acute neurologic complications during their entire stay in the hospital. The observed acute neurologic complications were hemiparesis and recurrent seizures in 3 patients, hearing impairment in 2 patients, and quadripareisis, cranioptosis, and vision impairment each in a patient (TABLE 3).

In general, a total of 69 patients (77.5%) improved, 8 (9%) died, 5 (5.6%) referred for further management of the neurologic complications, and 7 (7.9%) withdrew from the treatment with a delayed fever (poor condition) for unknown reasons. Out of a total of 16 patients with delayed fever (TABLE 3), 9 patients later improved due to further

<table>
<thead>
<tr>
<th>Table 2. Drug regimen used in children treated for BM in JUSH during February 25- April 29, 2015.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Regimens</strong></td>
</tr>
<tr>
<td>------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Initial regimen</strong></td>
</tr>
<tr>
<td>Ampicillin plus Gentamycin</td>
</tr>
<tr>
<td>Ceftriaxone plus Gentamycin</td>
</tr>
<tr>
<td>Crystalline Penicillin plus Chloramphenicol</td>
</tr>
<tr>
<td>Ceftriaxone alone</td>
</tr>
<tr>
<td><strong>Regimen changed to</strong></td>
</tr>
<tr>
<td>Ceftriaxone plus Gentamycin</td>
</tr>
<tr>
<td>Ceftriaxone alone</td>
</tr>
<tr>
<td>Ceftazidime plus Vancomycin</td>
</tr>
<tr>
<td><strong>Median duration (hours) to treatment from diagnosis (IQR)</strong></td>
</tr>
<tr>
<td>1(0.3-3.0)</td>
</tr>
<tr>
<td><strong>Mean duration to AB change (days, ± SD)</strong></td>
</tr>
<tr>
<td>5(2.0-8.0)</td>
</tr>
<tr>
<td><strong>Median delay of treatment from initial illness (IQR)</strong></td>
</tr>
<tr>
<td>32(10.2-73.5)</td>
</tr>
<tr>
<td><strong>Number of AB doses missed</strong></td>
</tr>
<tr>
<td>1 or 2</td>
</tr>
<tr>
<td>≥ 3</td>
</tr>
<tr>
<td><strong>Reasons for missing</strong></td>
</tr>
<tr>
<td>Unaffordability</td>
</tr>
<tr>
<td>IV line unavailable</td>
</tr>
<tr>
<td><strong>Dexamethasone use</strong></td>
</tr>
<tr>
<td>-</td>
</tr>
<tr>
<td><strong>Duration to dexamethasone with reference to Abs</strong></td>
</tr>
<tr>
<td>At same time or within 20 minutes before ABs</td>
</tr>
<tr>
<td>Beyond 20 minutes or after ABS</td>
</tr>
</tbody>
</table>

SD- standard deviation, IQR- interquartile range, CSF- cerebrospinal fluid
management and supportive care given within the ward (TABLE 4).

**Predictors of poor outcomes of BM in young infants**

Fifteen patients out of 53 young infants treated for BM (28.3%) had poor outcomes (TABLE 3). Sixty six percent (35/53) of young infants treated for BM were males (TABLE 1). The occurrence of poor outcomes in young infants was less likely for males compared to females, but it was not statistically significant. (AOR=0.285, 95% CI (0.068-1.193)). Delivery assisted by caesarean section was done in 31% infants under 2 months of age (TABLE 1). Infants whose delivery aided by Caesarian section experienced a 2 fold risk of poor outcomes than those delivered vaginally, however the difference was not statistically significant, AOR=2.015, 95% CI (0.292-13.907).

Only 5 patients (9.4%) presented with severe dyspnea among young infants (TABLE 1). Patients with severe dyspnea prior admission were 5 times more likely to have poor outcomes than those without severe dyspnea (AOR= 5.335, 95% CI (0.567-50.209)), however no significant difference observed between the two.

In young infants the frequently used initial regimen has been Ampicillin plus Gentamycin (86.8%), while only 13.2% of patients were given Ceftriaxone plus Gentamycin for initial management (TABLE 2). Initial AB regimens were either changed or modified only in 15 patients (28.3%) of this age group. Most of the AB changes were modifications of the initial Ampicillin plus Gentamycin to Ceftriaxone plus Gentamycin (13/15, 86.7%), whereas in only 2 cases the initial AB regimen was changed to Vancomycin plus Cefazidime (13,3%). The risks of experiencing poor outcomes were highly associated with changing the initial ABs than completing the whole course of treatment with the initial ABs with AOR=4.425, 95% CI (1.007-19.440). During the course of treatment, 12 patients (22.6%) missed at least one dose of their ABs (TABLE 2). Of these: 8 patients missed 1 or 2 doses and 4 patients missed 3 or more doses. Missing 1 or 2 doses of the prescribed ABs was found to increase the risk of experiencing poor outcomes as compared to patients who never missed their entire doses of ABs, however the difference was not statistically significant with AOR=3.708, 95% CI (0.615-22.364). Missing 3 or more doses also increased the occurrence of poor outcomes compared to

### Table 3. Treatment outcomes of children treated for BM in JUSH during February 25- April 29, 2015.

<table>
<thead>
<tr>
<th>Patients Outcomes</th>
<th>For ≤ 2months N=53</th>
<th>For &gt;2months N=36</th>
<th>General N=89</th>
</tr>
</thead>
<tbody>
<tr>
<td>Good outcomes/improved</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td>38(71.7)</td>
<td>22(61.1)</td>
<td>60(67.4)</td>
</tr>
<tr>
<td>Poor outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delayed fever</td>
<td>3(5.7)</td>
<td>5(13.9)</td>
<td>8(9.0)</td>
</tr>
<tr>
<td>Acute neurologic complication</td>
<td>10(18.8)</td>
<td>6(16.7)</td>
<td>16(18.0)</td>
</tr>
<tr>
<td>Median time to improvement (days, IQR)</td>
<td>6(3.0-9.2)</td>
<td>4(3.0-7.0)</td>
<td>5(3.0-8.5)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>n=89</th>
</tr>
</thead>
<tbody>
<tr>
<td>quadriparesis (1 patient) &amp; craniocytosis (1 patient),</td>
<td></td>
</tr>
<tr>
<td>hemiparesis and recurrent seizures (3 patients), &amp;</td>
<td></td>
</tr>
<tr>
<td>visionary impairment (1 patient), hearing impairment (2 patients)</td>
<td></td>
</tr>
</tbody>
</table>

### Table 4. General status at discharge of children treated for BM in JUSH during February 25- April 29, 2015.

<table>
<thead>
<tr>
<th>Statuses at discharge</th>
<th>Young infants N=53</th>
<th>Older infants &amp; children N=36</th>
<th>General N=89</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improved</td>
<td>44(83.0)</td>
<td>25(69.4)</td>
<td>69(77.5)</td>
</tr>
<tr>
<td>Died</td>
<td>3(5.7)</td>
<td>5(13.9)</td>
<td>8(9.0)</td>
</tr>
<tr>
<td>Neurologic complication (referred)</td>
<td>2(3.8)</td>
<td>3(8.3)</td>
<td>5(5.6)</td>
</tr>
<tr>
<td>Lost to follow up with delayed fever</td>
<td>4(7.5)</td>
<td>3(8.3)</td>
<td>7(7.9)</td>
</tr>
<tr>
<td>Median time to death in days, (IQR)</td>
<td>4(7.5)</td>
<td>3(8.3)</td>
<td>5(3.25-6.00)</td>
</tr>
<tr>
<td>Median hospital stay in days (IQR)</td>
<td>14(10-16)</td>
<td>12(9-15)</td>
<td>13(10-15)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>n=89</th>
</tr>
</thead>
<tbody>
<tr>
<td>quadriparesis (1 patient) &amp; craniocytosis (1 patient),</td>
<td></td>
</tr>
<tr>
<td>hemiparesis and recurrent seizures (3 patients), &amp;</td>
<td></td>
</tr>
<tr>
<td>visionary impairment (1 patient), hearing impairment (2 patients)</td>
<td></td>
</tr>
</tbody>
</table>
Predictors of poor outcomes of BM in older infants and children

Among the 36 older infants and children treated for BM, 14 patients (38.9%)...
experienced poor outcomes (TABLE 3). The majority (61.1%) of older infants and children treated for BM were males (TABLE 1). Lower incidence of poor outcomes of BM was observed in males compared to females with (AOR=0.123, 95% CI 0.03-5.890); but the difference was not statistically significant. In older infants and children clinical presentations characterized by irritability was 19.4% and seizure 61.1% on admission (TABLE 1). Patients who had an irritable clinical feature prior to admission were at nearly 38.4 times more increased risks of poor outcomes than those without this feature (AOR=38.388, 95% CI (1.777-829.357)). Seizure prior admission was also found to be associated with about 27.5 times increased incidence of poor outcomes compared to patients who had not seizure prior admission (AOR=27.529, 95% CI (1.451-522.346)).

Twenty one patients among older infants and children (61.1%) had different types of comorbidities. Of these 6 patients (28.6%) had sepsis, 5 patients (23.8%) had malaria, and 10 patients (47.6%) had either of pertussis, HIV, impetigo, moderate diarrhea, SAM and/or anemia (TABLE 1). Even though the presence of comorbidities was not statistically significant its presence seemed to increase the incidences of poor outcomes (AOR=8.413, 95% CI, (0.430-164.664)).

In older infants and children the most commonly used initial AB regimen was crystalline penicillin plus Chloramphenicol (69.4%). Ceftriaxone plus Gentamycin and Ceftriaxone alone were also the other initial AB regimens given to patients of this age group in 25% and 5.6% of patients respectively (TABLE 2). An initial regimen with Ceftriaxone plus Gentamycin was found to be a strong predictor of poor outcomes (p=0.007). As compared to patients who initially treated with Crystalline penicillin plus Chloramphenicol, those initially treated by Ceftriaxone plus Gentamycin were highly associated with increased incidence of poor outcomes (AOR=66.480, 95% CI (3.157-1400.127)). However, longer than 1 hour delay in treatment from diagnosis failed to show statistically significant association with poor outcomes (AOR=1.985, 95% CI (0.076-52.162)). During the course of treatment 11 patients (30.6%) missed at least one dose of their prescribed ABs. Of these 9 patients missed either 1 or 2 doses, while the remaining 2 patients missed 3 or more doses (TABLE 2). Patients who missed either 1 or 2 doses of ABs during the entire course of treatment were found to be at about 47 times more risks of experiencing poor outcomes compared to those never missed their doses (AOR=47.329, 95% CI (2.141-1046.186)).

**Discussion**

Early initiation of an optimal antibiotic therapy for confirmed or suspected BM, pending the CSF results, has been shown to be one of the most important factor to reduce morbidity and lethality (4,5,9,10,54-57). In the current study, most of the young infants (86.8%) were initially treated with empiric Ampicillin plus Gentamycin regimen. On the other hand, in older infants and children, the most commonly used empiric AB regimen was Crystalline penicillin plus Chloramphenicol (66.7%) followed by Ceftriaxone plus Gentamycin (25%). The selection and timing of initiation of ABs were in line with the current recommendation for developing countries [39]. The choice of ABs was also similar to studies conducted in some resource limited settings. The median duration of treatment from diagnosis for both age groups was the similar, 1 hour. This was similar to the study from Italy (1 hour) and even better than that from Uganda (9.6 hours) [40,41].

Meanwhile, in the course of treatment, in 20% of patients ABs changes were considered due to poor response to the empiric regimen. Among young infants for whom ABs change was considered, in most (87%) of the cases the empiric Ampicillin plus Gentamycin was modified to Ceftriaxone plus Gentamycin, and only 3 patients the regimen changed to Ceftazidime plus Vancomycin. The change was also in agreement with current recommendations as almost all the changes were made to the first line alternative considering affordability as per the recommendation for resource limited countries of WHO. Guidelines and current evidence recommend narrowing of the empiric regimen as soon as the agent is identified or change of empiric ABs within 2-3 days in cases if it is not possible to identify the agent and the patient is not improving with the empiric ABs [42]. However, the duration to change of ABs in our case was very longer than the recommended. The mean duration of AB change for young
infants was 5 days while it was 3.2 days for older
infant and children.

Generally, nearly 67% of patients treated
for BM improved within 7 days of treatment
without acute complications and the median
time for improvement was 5 days. This was
better than a study done in Uganda at that
time to improve from initiation of treatment
was 10.3 days. The difference could be due to
delayed presentation (median=6.5 days) and
late initiation of treatment (median=9.6 hours)
from Uganda’s study compared to median time
to hospital presentation was only 2 days and
median time to treatment was only 1 hour in
the current study. The cumulative incidence
of poor outcomes in this study was 32.6%;
including mortality of 9%, acute neurologic
complications (6%), and delayed fever in 18%
of patients (TABLE 3). The incidence of poor
outcomes was almost comparable with most
studies from resource limited settings [43-45]
but it could be slightly lower than those reports
since only the short-term treatment outcomes
were included and had no follow up after
discharge that would increase the rate of both
mortality and neurologic complications in those
studies.

Among patients initially treated with
Ampicillin plus Gentamycin, almost 85%
improved without complications and 15%
had poor outcomes while in patients initially
treated with a combination of Ceftriaxone and
Gentamycin, about 71% improved without
acute complications 29% experienced poor
outcomes. The patients initially treated with
Ceftriaxone plus Gentamycin experienced
comparatively poorer outcomes, as those
patients initially presented with severe clinical
feature (like a seizure) at admission.

The incidences of poor outcomes within
7 days of treatment were different when the
two age groups compared; nearly 28% of the
young infants versus 39% of the older infants
and children (TABLE 3). The majority of the
older infants and children (57%) presented
to the hospital late (after 2 days of illness),
whereas only 36% of young infants presented
after 2 days. However, this difference in delayed
presentation with age was not statistically
significant on univariate analysis (COR=2.3,
p=0.061). The median age of the younger
infants was 6 days, which might indicate most

Predictors of poor outcomes in
young infants

In young infants, despite the percentage
of males treated was quite higher (66%) and
those had poor outcome still higher (53%),
the risk of experiencing poor outcomes seemed
lower compared to females, but this failed
to show statistically significant association in
multivariate logistic regression. In the same
manner, caesarean section aided delivery initially
seemed to increase the risk of poor outcomes
compared to vagina delivery, however it was not
found to be one of the important predictors of
poor outcomes.

In the present study, the presence of severe
dyspnea at admission was found to increase
the risk of poor outcomes; but statistically
significant association with poor outcomes
was not determined under multivariate logistic
regression. This was similar to the study of
Pelkonen et al. in which severe dyspnea before
admission showed a non-significant increase
in the risks of developing severe neurological
sequelae and significantly increased the risk of
death [46].

Young infants for whom empiric AB changed
were associated with increased incidence of
poor outcomes than those completed their
entire course of treatment with the initial AB
regimen. First of all, patients for whom ABs
changed were those critically ill or those did
not improve to the empiric regimen. Secondly,
the mean duration of AB change was 5 days,
which was much longer than the recommended
(2-3 days). Furthermore, most of the patients
(93%) who ABs was changed had one or more
comorbidities. Therefore, the higher percentage
of comorbidities in patients who had AB
changes could have contributed to the poor outcomes as the difference was significant on univariate logistic regression (p=0.026), and the longer duration of time to AB changes could also have contributed to. In addition, in some studies, it was highlighted that most of the patients in developing countries have delayed presentation to the higher health care settings having been treated with common 3rd generation cephalosporin (mainly Ceftriaxone) without a definite diagnosis in primary or private settings [41,47]. Consequently, these could have its own impact on the sensitivity of the pathogens to these antibiotics, but this needs further investigation. Even though statistically significant difference was not observed, missing one or more doses of the prescribed ABs had increased the risk poor outcomes in the current study. As the main reason for missing was unaffordability, really this needs intervention by improving effective communication of the health care team with patients' family or caregivers and facilitating the opportunities for them on how to get alternative cost effective therapies.

Predictors of poor outcomes in older infants and children

In this study, despite the gender distribution was predominated by males (61%), female gender had contributed a higher percentage (57%) to the poor outcomes of BM. Interestingly; this gender difference was not statistically significant. Delayed presentation to the hospital (after 72 hours of illness) was higher in females (36%) versus 27% in males. Ahmed A. in his study at Gonder and Hawassa highlighted that, there are still social and cultural factors that favor easier access for males to the healthcare facilities as compared to the females and even those females that attend the health care facilities are after the disease got advanced/complicated [3]. This may also highlight the bias or the preference that may be given by the family to the male children over the female children which need further research.

Many clinical features prior to or at hospital admission are associated with the outcome of bacterial meningitis [47,48]. In the current study, irritable feature at presentation found to increase the incidence of poor outcomes, as this feature is mostly a manifestation of CNS disorders characterized by abnormal sensitivity signifying the advanced nature of the disease. Similarly, the presence of seizure at or prior to admission was associated with increased incidence of poor outcomes. This is in line with different studies in which the occurrence seizure prior hospital admission increased mortality and sever neurological sequelae, as the occurrence of seizure at presentation indicates the advanced stage (complication) of the disease.

About 58% of older infants and children treated for BM had one or more comorbidities. These included sepsis in 6 (29%) patients, malaria in 5 (24%), and in 10 children other comorbidities (like pertussis, HIV, impetigo, moderate diarrhea, SAM and/or anemia). The incidence of poor outcomes was 39% and there were consistently increased incidence of poor outcomes, in both univariate and multivariate logistic regression, in patients who had one or more comorbidities though it was not statistically significant. The possible explanation could be most of these comorbidities were clinical suspicions due to the similarity of clinical features like sepsis and malaria with that of BM rather than laboratory confirmation. Another possible reason that needs further evaluation was; probably there could be proper management of these comorbidities, though the management was not presented here. This was similarly not significant in the study of Prishtina (Kosovo).

The most commonly used initial AB regimen in older infants and children was crystalline penicillin plus Chloramphenicol (66.7%) followed by a combination of ceftriaxone and gentamycin (25%). Out of the 24 patients (66.7%) initially treated with crystalline penicillin plus Chloramphenicol, 79.2% improved without acute complications and the remaining 20.8% had poor outcomes. However, among 9 patients (25%) that were initially given a combination of Ceftriaxone and Gentamycin, almost half (44.4%) experienced poor outcomes. An initial regimen with Ceftriaxone plus Gentamycin instead of the first line crystalline penicillin plus Chloramphenicol significantly increased the risk of poor outcomes. First of all, the main indication for selection of Ceftriaxone based regimen instead of first line penicillin/ampicillin based regimen in the ward was severe (critical illness) at presentation. Secondly, in the majority (75%) patients initially put on Ceftriaxone plus Gentamycin the initial dose of the drugs was administered lately (after 1 hour of diagnosis) compared to only in16% of patients...
on Crystalline penicillin plus Chloramphenicol
the drugs were initiated lately (after 1 hour
of diagnosis). The reason for the delay could
be due to searching of this expensive drug
(Ceftriaxone compared to Penicillin) since it is
not commonly available in our wards. Thirdly,
there were a higher percentage of patients with
comorbidities during the course of treatment,
67% of ceftriaxone based against 53% for
penicillin based. Besides, the use of adjuvant
dexamethasone was lower (33% versus 54%)
and not fully vaccinated were higher (78% versus 33%)
in patients on Ceftriaxone based regimen compared to patients on Penicillin
based regimen respectively. Therefore, the
increased incidence of poor outcomes among
patients on a Ceftriaxone based regimen than
those on Penicillin should not be surprising in
the presence of all of the above factors that could
contribute to poorer outcomes.

However, in a Cochrane review of
randomized controlled trials (RCTs), the
effectiveness and safety of Ceftriaxone or
Cefotaxime were compared with conventional
treatment with Penicillin or Ampicillin plus
Chloramphenicol in patients with community-
acquired acute bacterial meningitis. No clinically
important difference between Ceftriaxone or
Cefotaxime and conventional antibiotics was
identified. Pelkonen T. et al in the study among
the Sub-Saharan Africa children also showed
the evidence that supported the finding of a
Cochrane review above in that, treatment with
ceftriaxone instead of with the primary regimen
of Penicillin plus Chloramphenicol, did not
improve the prognosis.

On the other hand, the report from
KOSOVO showed that, the risk for developing
neurologic complications and mortality was
very high in patients treated with the initial
antimicrobial therapy using Ceftriaxone
alone or with Chloramphenicol than those
initially treated with Penicillin G alone or with
Chloramphenicol. Similarly, Theodoridou
et al. also reported that, third-generation
cephalosporin was related to an increased
risk of hydrocephalus and ventriculitis, and
the use of Penicillin was found to have a
protective effect against neurologic sequelae
(48). The strength of the last study in showing
higher rates of neurotoxicity associated with
cephalosporin compared to penicillin is that, it
used multinomial logistic regression to identify
the association among the different AB regimens
with specific types of neurologic complications.
But the current study used binomial logistic
regression in that the association with
neurotoxicity was not clearly known [48].

In the current study, another factor related
to ABs found to have a statistically significant
association with poor outcomes was number of
missed ABs dose. Patients who missed one or
more doses of their prescribed ABs experienced
more pronounced poor outcomes than
those never missed their ABs dose. As it was
mentioned above under young infants section,
this could highlight the need of intervention by
narrowing the gap between the health care team
and patients’ family or caregivers by working
together and searching for all possible options
for the benefit of the patients.

Strengths and limitations of the
study
Our study has some strength. Firstly, the
design was prospective observational hospital
based study in which most relevant variables
were collected. Secondly, it was the first study
in the country to study the outcomes of BM
associated with ABs use. However, our study
was not free of limitation and needs precaution
in interpreting. To mention some: the study
period was short due to time limitation which
couldn’t allow collecting enough sample size,
which resulted in wider ranges of confidence
intervals. In addition, it would have been better
if the patients were followed for some time after
discharge to get the full impact of the disease
so that complete outcomes could be measured.
Because of that sever neurologic sequelae could
not be detected within this short period; instead
the data were limited to short-term acute
complications.

The other important factor common to
most resource limited settings was the lack
of availability of some important laboratory
facilities in which most of the cases of the
current study were not confirmed by laboratory
evidence, instead of the clinical diagnosis which
may be less accurate than the laboratory assisted
one.

Lastly, lack of studies regarding sensitivity of
causative agents to the existing antimicrobials
in our setups could impact treatment as well as
comparisons of the regimens in this study.
**Conclusion**

In the current study the selection of empiric therapy, change of empiric regimen as well as the timing of antimicrobials for treatment of childhood BM was almost consistent with recommendations for resource limited settings except that the timing of empiric antibiotics change was much longer. At discharge nearly one-fourth of the patients treated for BM experienced poor outcomes.

Finally, some independent predictors of poor outcomes were identified. In young infants, change of empiric antibiotics during the course of treatment was found to independently predict the incidence of poor outcomes. Whereas, in older infants and children, severe clinical presentations characterized by irritability and seizure prior hospital admission and drug related factors including initial treatment with a combination of Ceftriaxone and Gentamycin instead of first line Crystalline penicillin plus Chloramphenicol and missing one or more doses of the prescribed antibiotics during the course of treatment were found to independently increase incidence of poor outcomes.

**Recommendations**

The hospital has to create awareness of the health care team to give due attention for patients presented with severe clinical features like seizure and irritability as these were the alarming signs of poor outcomes. The hospital and concerned bodies should also follow and strengthen effective communication between the health care team and patients (family/care givers) since their non-compliance (missing their prescribed ABs doses) were found to implicate poor prognosis. As this can be solved by improving the interaction between the patient (family/care givers) and the health care team to create common understanding for the benefit of the patient, thereby searching for and facilitating all the possible options for the patient (family/care givers) on how to get the cost effective alternatives. In addition, the study could highlight the need for revising management protocols regarding timing of the change of empiric ABs for children with BM in this ward.

The current study could also highlight that the need for further study with large sample size and longer study period and other studies that focuses on antimicrobial sensitivity in the setup.

**Ethics approval and consent to participate**

Ethical clearance was obtained from the institutional review board of Jimma University, college of health sciences. Patient consent was obtained from care givers or family in a written form by 2 local languages (Afan Oromo and Amharic) prior data collection.

**Availability of data and material**

The datasets generated and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.

**Competing interests**

The authors declared that they have no competing interests.

**Funding**

No specific funding was received for this work.

**Authors' contributions**

HA designed the study, carried out an analysis and interpreted the patient data, and drafted the manuscript. SH participated in the design of the study, supervised, coordinated and helped to draft the manuscript. LC participated in the design of the study, supervised, coordinated and helped to draft the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

First of all we would like to acknowledge JU and JUSH for permitting us to conduct the study and JUSH pediatric ward staffs for their support during data collection. Furthermore, our sincere appreciation also goes to our study participants and their family/care givers who voluntarily and genuinely gave their time as well as information.
REFERENCES


This special issue on Current Trends in Clinical Research was edited by Dr. Mohamed Elsayed.